[{"id":"38aae3c4-f386-4a60-a95e-c6b46ee44656","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656248","created_at":"2022-12-19T14:58:46.031Z","updated_at":"2025-02-25T14:41:44.924Z","phase":"Phase 2","brief_title":"Study of CPX-351 (VYXEOS) in Individuals \u003c 22 Years With Secondary Myeloid Neoplasms","source_id_and_acronym":"NCT05656248","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26","pipe":"","alterations":" ","tags":["TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-14"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"8ac311e1-51b9-4db1-ab2f-31550ca1d3bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762381","created_at":"2021-02-21T13:52:19.658Z","updated_at":"2024-07-02T16:34:59.057Z","phase":"","brief_title":"Dexamethasone and Robotic-assisted Hysterectomy","source_id_and_acronym":"NCT04762381","lead_sponsor":"Herning Hospital","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"],"overall_status":"Completed","enrollment":" Enrollment 109","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 02/06/2024","primary_completion_date":" 02/06/2024","study_txt":" Completion: 02/06/2024","study_completion_date":" 02/06/2024","last_update_posted":"2024-06-04"},{"id":"b49b535d-c235-48c9-ba02-da606366f390","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT05405387","created_at":"2022-06-06T13:56:18.481Z","updated_at":"2024-07-02T16:35:19.702Z","phase":"Phase 2","brief_title":"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","source_id_and_acronym":"NCT05405387 - IMPACT","lead_sponsor":"University of Utah","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/09/2023","start_date":" 02/09/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-02-13"},{"id":"7465a53d-edcc-499b-8a80-50f901ea6413","acronym":"HO147SMM","url":"https://clinicaltrials.gov/study/NCT03673826","created_at":"2021-01-18T18:01:13.776Z","updated_at":"2024-07-02T16:35:30.805Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM","source_id_and_acronym":"NCT03673826 - HO147SMM","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" PTPRC • NCAM1","pipe":"","alterations":" ","tags":["PTPRC • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/19/2018","start_date":" 11/19/2018","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-11-01"},{"id":"1c785025-f43b-4883-8f63-f4781a546652","acronym":"","url":"https://clinicaltrials.gov/study/NCT00869232","created_at":"2021-01-18T03:19:09.867Z","updated_at":"2024-07-02T16:35:40.540Z","phase":"Phase 2","brief_title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","source_id_and_acronym":"NCT00869232","lead_sponsor":"University of Arkansas","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-08-09"},{"id":"5766f363-23d7-4ddf-aa99-822a48d173b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02185820","created_at":"2021-02-04T20:52:56.667Z","updated_at":"2024-07-02T16:35:44.252Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)","source_id_and_acronym":"NCT02185820","lead_sponsor":"European Myeloma Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-06-30"},{"id":"28b858c7-a69c-411d-b45b-24caa5e929cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02819024","created_at":"2021-01-18T13:49:27.957Z","updated_at":"2024-07-02T16:35:48.808Z","phase":"","brief_title":"Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography","source_id_and_acronym":"NCT02819024","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" NR3C1","pipe":"","alterations":" ","tags":["NR3C1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 11/08/2022","primary_completion_date":" 11/08/2022","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-05-05"},{"id":"cae9ba53-3324-4a13-b8d1-3231a1c74020","acronym":"","url":"https://clinicaltrials.gov/study/NCT00587067","created_at":"2021-01-18T02:09:44.392Z","updated_at":"2024-07-02T16:35:51.530Z","phase":"Phase 2","brief_title":"A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy","source_id_and_acronym":"NCT00587067","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 06/01/2003","start_date":" 06/01/2003","primary_txt":" Primary completion: 05/19/2016","primary_completion_date":" 05/19/2016","study_txt":" Completion: 05/19/2016","study_completion_date":" 05/19/2016","last_update_posted":"2023-04-04"},{"id":"94fe4903-a2c9-42e8-862b-770fa6d33088","acronym":"I-HEP","url":"https://clinicaltrials.gov/study/NCT04810156","created_at":"2021-03-22T11:52:24.698Z","updated_at":"2025-02-25T14:02:17.911Z","phase":"Phase 2","brief_title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","source_id_and_acronym":"NCT04810156 - I-HEP","lead_sponsor":"Inge Marie Svane","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prednisone • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/07/2025","primary_completion_date":" 04/07/2025","study_txt":" Completion: 11/07/2025","study_completion_date":" 11/07/2025","last_update_posted":"2022-12-14"},{"id":"a6fd0405-fc77-45a8-8618-63d6afa0c28a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04797325","created_at":"2021-03-15T15:53:37.014Z","updated_at":"2024-07-02T16:36:05.376Z","phase":"Phase 2","brief_title":"Vedolizumab for Immune Mediated Colitis","source_id_and_acronym":"NCT04797325","lead_sponsor":"University of Copenhagen","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Entyvio (vedolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-08-17"},{"id":"3a0c49c1-727b-492b-bc54-7034bb716618","acronym":"KMM1911","url":"https://clinicaltrials.gov/study/NCT05497102","created_at":"2022-08-15T11:10:45.029Z","updated_at":"2024-07-02T16:36:05.577Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","source_id_and_acronym":"NCT05497102 - KMM1911","lead_sponsor":"Samsung Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-08-12"},{"id":"74b3ecbf-9728-4d5a-931f-2e42f941235f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04588857","created_at":"2021-01-18T21:53:18.276Z","updated_at":"2024-07-02T16:36:14.950Z","phase":"Phase 4","brief_title":"Efficacy of a Single Dose Dexamethasone in Reducing the Postembolization Syndrome in Men Undergoing Prostatic Artery Embolization for Benign Prostatic Hyperplasia","source_id_and_acronym":"NCT04588857","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-03-22"},{"id":"019e5c1f-7cc6-4bf5-9b54-11b80b290251","acronym":"","url":"https://clinicaltrials.gov/study/NCT03375567","created_at":"2021-01-29T07:16:40.130Z","updated_at":"2024-07-02T16:36:16.671Z","phase":"","brief_title":"Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone","source_id_and_acronym":"NCT03375567","lead_sponsor":"Yale University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2022-02-24"},{"id":"833dd095-7417-4e0f-960a-d105ef27505c","acronym":"COVERAGE","url":"https://clinicaltrials.gov/study/NCT04356495","created_at":"2021-01-29T07:20:37.661Z","updated_at":"2024-07-02T16:36:17.584Z","phase":"Phase 2/3","brief_title":"Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation","source_id_and_acronym":"NCT04356495 - COVERAGE","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Completed","enrollment":" Enrollment 412","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 10/22/2021","study_completion_date":" 10/22/2021","last_update_posted":"2022-02-04"},{"id":"6bf16149-61da-4e07-89da-5c263485c4ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT00075829","created_at":"2021-01-18T00:12:12.016Z","updated_at":"2024-07-02T16:36:22.026Z","phase":"Phase 3","brief_title":"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)","source_id_and_acronym":"NCT00075829","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 710","initiation":"Initiation: 12/01/2003","start_date":" 12/01/2003","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2021-11-01"},{"id":"44396421-a910-4d21-ab72-d4ff0149634c","acronym":"GBMdexaB","url":"https://clinicaltrials.gov/study/NCT04128774","created_at":"2021-01-18T20:10:15.489Z","updated_at":"2024-07-02T16:36:22.278Z","phase":"","brief_title":"Function and Composition of Regulatory B Cells in Participants With Glioblastoma","source_id_and_acronym":"NCT04128774 - GBMdexaB","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" IL2RA • ISG20","pipe":"","alterations":" ","tags":["IL2RA • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-10-28"},{"id":"49e4f33c-cb35-4117-ab0d-d9268b78e88a","acronym":"REDEX","url":"https://clinicaltrials.gov/study/NCT02776436","created_at":"2021-01-18T13:36:52.846Z","updated_at":"2024-07-02T16:36:32.448Z","phase":"Phase 1","brief_title":"Reducing Dexamethasone Around Docetaxel Infusion","source_id_and_acronym":"NCT02776436 - REDEX","lead_sponsor":"Leiden University Medical Center","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2021-04-02"},{"id":"f60e6b64-d4a6-4c87-b498-d69b76e6150f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01402284","created_at":"2021-01-18T05:45:42.710Z","updated_at":"2025-02-25T14:32:59.232Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","source_id_and_acronym":"NCT01402284","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 07/21/2011","start_date":" 07/21/2011","primary_txt":" Primary completion: 07/10/2016","primary_completion_date":" 07/10/2016","study_txt":" Completion: 09/24/2020","study_completion_date":" 09/24/2020","last_update_posted":"2021-03-02"},{"id":"ed6ae788-f12f-4a38-a73d-cfa2405c9257","acronym":"","url":"https://clinicaltrials.gov/study/NCT01647165","created_at":"2021-01-29T07:03:28.608Z","updated_at":"2025-02-25T14:56:29.350Z","phase":"Phase 2","brief_title":"Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance","source_id_and_acronym":"NCT01647165","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/11/2012","start_date":" 07/11/2012","primary_txt":" Primary completion: 06/26/2015","primary_completion_date":" 06/26/2015","study_txt":" Completion: 06/26/2015","study_completion_date":" 06/26/2015","last_update_posted":"2019-12-12"},{"id":"1b99ec7f-1ee5-4321-a2cb-6d2b36a57f79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02520115","created_at":"2023-10-15T04:13:10.765Z","updated_at":"2024-07-02T16:36:56.952Z","phase":"Phase 1","brief_title":"Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer","source_id_and_acronym":"NCT02520115","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2019-08-14"},{"id":"36cf4d45-d640-4301-9c98-715cbdd5a9d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01852799","created_at":"2021-01-18T08:16:19.638Z","updated_at":"2024-07-02T16:37:08.000Z","phase":"Phase 2","brief_title":"A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma","source_id_and_acronym":"NCT01852799","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • doxorubicin hydrochloride • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2018-08-10"},{"id":"2d56cada-8b85-4aef-a0ec-81a7546676fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00310102","created_at":"2021-01-18T01:04:01.662Z","updated_at":"2024-07-02T16:37:19.170Z","phase":"Phase 2","brief_title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Treating Patients With Primary Liver Cancer That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00310102","lead_sponsor":"Wake Forest University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 09/01/2004","start_date":" 09/01/2004","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2017-08-04"},{"id":"ae4669e3-d259-4b4b-bb90-9868c90fd1ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT00148317","created_at":"2021-01-18T00:30:19.959Z","updated_at":"2025-02-25T14:54:12.506Z","phase":"Phase 2","brief_title":"Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma","source_id_and_acronym":"NCT00148317","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • pegylated liposomal doxorubicin • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 06/01/2005","start_date":" 06/01/2005","primary_txt":" Primary completion: 02/01/2011","primary_completion_date":" 02/01/2011","study_txt":" Completion: 11/01/2012","study_completion_date":" 11/01/2012","last_update_posted":"2017-07-18"}]